USFDA approves AstraZeneca Calquence, bendamustine, rituximab combo for previously untreated mantle cell lymphoma Ruchika Sharma18 Jan 2025 1:30 PM ISTCambridge: AstraZeneca has announced that the Food and Drug Administration (FDA) has approved Calquence (acalabrutinib) in combination with...
AstraZeneca-Daiichi Sankyo Datopotamab deruxtecan gets USFDA priority review in pretreated EGFR-mutated non-small cell lung cancer Ruchika Sharma14 Jan 2025 2:30 PM ISTDatopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody drug conjugate discovered by Daiichi Sankyo.
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal To Study antihypertensive drug Baxdrostat Dr. Divya Colin29 Dec 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the pharmaceutical...
AstraZeneca Gets CDSCO Panel Nod To study Anti-Cancer Drug Rilvegostomig Dr. Divya Colin27 Dec 2024 6:00 PM ISTNew Delhi: Pharmaceutical major AstraZeneca has got approval from the Subject Expert Committee (SEC) functional under the Central Standard Control...
AstraZeneca Tagrisso approved in EU for patients with unresectable EGFR-mutated lung cancer Ruchika Sharma27 Dec 2024 11:30 AM ISTCambridge: AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with...
AstraZeneca, Daiichi Sankyo voluntarily withdraws datopotamab deruxtecan application in EU for lung cancer Ruchika Sharma25 Dec 2024 11:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo have voluntarily withdrawn the marketing authorisation application (MAA) in the EU for datopotamab...
Pfizer, AstraZeneca and several other drugmakers in race to join weight loss drug market Ruchika Sharma23 Dec 2024 5:01 PM ISTPfizer, AstraZeneca, Amgen and several other drug developers aiming to join the weight-loss drug market, which is estimated to be worth about $150...
CDSCO Panel Approves AstraZeneca's Protocol Amendment Proposal For Anti-cancer Drug Volrustomig study Dr. Divya Colin22 Dec 2024 6:00 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved AstraZeneca's...
CDSCO panel approves AstraZeneca's Protocol Amendment proposal for Anticancer Drug AZD5305 study Dr. Divya Colin15 Dec 2024 5:30 PM ISTNew Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the drug major...
AstraZeneca-Daiichi Sankyo Datopotamab deruxtecan gets USFDA Breakthrough Therapy Designation for previously treated advanced EGFR-mutated non-small cell lung cancer Ruchika Sharma10 Dec 2024 12:30 PM ISTCambridge: AstraZeneca has announced that Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy Designation (BTD) in the...
AstraZeneca Imfinzi granted priority review by USFDA for muscle-invasive bladder cancer Ruchika Sharma7 Dec 2024 12:30 PM ISTCambridge: AstraZeneca's supplemental Biologics License Application (sBLA) for Imfinzi (durvalumab) has been accepted and granted Priority Review...
AstraZeneca Imfinzi gets USFDA nod for limited-stage small cell lung cancer Ruchika Sharma6 Dec 2024 11:00 AM ISTAstraZeneca's Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer...
